Adstiladrin
nadofaragene firadenovec · IFN-alpha2b (adenovirus, intravesical)22 (derived from the dosing and observation schedule)
Vyjuvek: how long were the pivotal tox studies?
beremagene geperpavec · COL7A1 (HSV-1, topical)
Longest pivotal study
9 (derived from the dosing and observation schedule)
“The remaining animals were sacrificed on Day 30 or allowed to recover for an additional 30 days following completion”
Pivotal GLP studies
GLP BALB/c mouse studies: single IV; 5 weekly intradermal doses with 30-day recovery; single topical to wounded skin
“five repeat weekly ID administrations of VYJUVEK in BALB/c mice at 6.9 x 106 or 3.45 x 107 pfu/mouse/administration”
Route in tox
Intradermal, topical (wounded skin) and intravenous (mice)
“single topical application of VYJUVEK mixed with 3% HPMC to wounded skin of BALB/c mice at 3.48 x 107 pfu/application.”
Same question, other gene therapies
Beqvez
fidanacogene elaparvovec · Factor IX104 weeks
Casgevy
exagamglogene autotemcel · BCL11A enhancer (CRISPR-Cas9, ex vivo HSC)20 weeks
Elevidys
delandistrogene moxeparvovec · Micro-dystrophin24 weeks
Fayuvi
rebisufligene etisparvovec · SGSH (AAV9)26 weeks
Genglycos
pariglasgene brecaparvovec · G6PC (AAV8)26 weeks
Glybera
alipogene tiparvovec · LPL (AAV1)26 weeks
Hemgenix
etranacogene dezaparvovec · Factor IX26 weeks
Imlygic
talimogene laherparepvec · GM-CSF (oncolytic HSV-1)12 (derived from the dosing and observation schedule)
Itvisma
onasemnogene abeparvovec (intrathecal) · SMN1 (AAV9, intrathecal)52 weeks
Kebilidi
eladocagene exuparvovec · AADC26 weeks
Kresladi
marnetegragene autotemcel · ITGB2 (LVV, ex vivo HSC)4 weeks
Lenmeldy
atidarsagene autotemcel · ARSA (LVV, ex vivo HSC)52 weeks
Luxturna
voretigene neparvovec · RPE6531 weeks
Lyfgenia
lovotibeglogene autotemcel · HBB T87Q (LVV, ex vivo HSC)26 weeks
Otarmeni
lunsotogene parvec · OTOF (AAV, intracochlear)27 weeks
Papzimeos
zopapogene imadenovec · HPV6/11 antigens (gorilla adenovirus)3 weeks
Roctavian
valoctocogene roxaparvovec · Factor VIII26 weeks
Skysona
elivaldogene autotemcel · ABCD1 (LVV, ex vivo HSC)13 (derived from the dosing and observation schedule)
Strimvelis
autologous CD34+ cells transduced with ADA (no INN) · ADA (gamma-retroviral, ex vivo HSC)16 weeks
Tudriqev
vusolimogene oderparepvec · GALV-GP + GM-CSF (oncolytic HSV-1)26 weeks
Waskyra
etuvetidigene autotemcel · WAS (LVV, ex vivo HSC)64 weeks
Zevaskyn
prademagene zamikeracel · COL7A1 (RV-modified keratinocyte sheets)8 weeks
Zolgensma
onasemnogene abeparvovec · SMN126 weeks
Zynteglo
betibeglogene autotemcel · HBB T87Q (LVV, ex vivo HSC)26 weeks